Wikipedia -WSS

Wikipedia

author：comprehensive 2025-09-14 11:46:53 - browse：33

As a new class of diabetes and obesity medications has soared in popularity, so have the online outlets built to get them in the hands of patients. A new analysis of claims data from Trilliant Health suggests that collectively, telehealth companies — in particular, cash-pay options that market directly to consumers — could account for many of the patients with insurance claims for GLP-1 prescriptions in 2022.

Direct-to-consumer telehealth companies have offered an easier on-ramp for many patients to access prescriptions for a variety of conditions. And since the first GLP-1s were approved for obesity — promising up to 15% weight loss — many of those companies have capitalized on the approvals and surging demand to launch new weight loss businesses. Companies including Calibrate and Ro claim to have reached tens and hundreds of thousands of patients with their weight loss medication programs.

Collectively, their reach may be even larger. The Trilliant Health analysis, conducted on behalf of STAT, offers an early glimpse of the foothold those businesses have gained in GLP-1 prescribing. In a nationwide claims database of more than 300 million patients using both commercial and federal insurance, Trilliant Health found about 3.6 million people with a prescription claim for a GLP-1 — semaglutide, tirzepatide, or injectable liraglutide without insulin — in 2022. To determine where each patient may have gotten those prescriptions, they looked for a medical visit claim within three days of a prescription claim for a GLP-1 — the visit where the script was likely written. But they only found a matching visit for 53% of patients.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： How a billionaire couple greased the skids for Pelosi’s drug pricing bill

entertainment

WSS

Study suggests new cause of Down syndrome: cells linked to aging

Readout LOUD podcast: Live from STAT Breakthrough Summit West

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

Allen Institute goes after foundational questions, CEO Costa says

At JPM 2024, hospital systems pitch financial strength to investors

Does Paxlovid work in people vaccinated against Covid

knowledge

Wikipedia

hotspot

Trump demands the U.S. pay no more for drugs than other countries … again

STAT Virtual Event: JPM Recap, Live!

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Arena BioWorks launches in Cambridge to speed drug discovery

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Nonprofit, backed by Microsoft, to certify AI tools in health care

Affirmative action in medical school literally saved lives

Life science postdocs should get big pay hike, NIH panel says

The high cost of giving birth even with insurance

Does Paxlovid work in people vaccinated against Covid

entertainment

Bird flu: Don't repeat Covid's 'health versus the economy' framing

Arc Institute generative AI designs new CRISPR systems

Venture capitalist Bob Kocher on the state of digital health

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

Merck to acquire Harpoon Therapeutics for $680 million

It's time to retire 'poor historian' from clinicians' vocabularies

knowledge

entertainment

entertainment

hotspot